SlideShare una empresa de Scribd logo
1 de 25
Data Quality Deconstructed:
Do more, plan less
Global Clinical Trials
14-Sep-2012 Boston

Eileen M. Daniel
Director, Clinical & Data Operations

©2012 Endo Pharmaceuticals, Inc. All rights reserved.

1
15+ years ago
New York City
Spring 1997

©2012 Endo Pharmaceuticals Inc. All rights reserved.

2
Today there is nothing new under the sun
… except maybe some clouds

©2012 Endo Pharmaceuticals Inc. All rights reserved.

3
During this talk, I will

–
–
–
–
–

remind us of fundamentals
provide facts about a global study
tell you where & why we liberally apply brakes
flashback to a deconstruction methodology
close with thoughts on site and study initiation

©2012 Endo Pharmaceuticals Inc. All rights reserved.

4
stating the obvious

©2012 Endo Pharmaceuticals, Inc. All rights reserved.

5
We all know this
The clinical trials we sponsor are research studies.
– A study is conducted according to a well-defined study plan
– That well-defined study plan is the protocol

Clinical investigators are responsible for conducting studies in
accordance with the protocol.
We are obliged to oversee and keep sharp focus on:
– Protection of human subjects
– Integrity of study data
– Compliance with applicable regulations

To meet our oversight obligations we conspire to plan.

©2012 Endo Pharmaceuticals Inc. All rights reserved.

6
the plans (sigh)

© 2012 Endo Pharmaceuticals Inc. All rights reserved.

7
The plans for a global phase 3 study
– 3.5 FTEs with global responsibility
study leader | data manager | study specialist | clinical information mgr

– 450 subjects recruited from 120 sites
North America, Europe, India

– 10 service partners including 4 CROs

– All study data flows in electronically from three sources
eCRF, central laboratory, IVRS

– 1 protocol, 1 playbook and 7 global plans

Bladder cancer is challenging enough. Starting up was hard to do.

©2012 Endo Pharmaceuticals Inc. All rights reserved.

8
Starting up – forming our global study community

study
community

study community >600
+clinical investigators & team

study team >30
study team

clinical sub
team

clinical trial
manager

+partner project managers

clinical sub-team >10
trial manager
research scientist
statistician
data manager
project management
regulatory affairs
health economics
pharmacovigilance …

Alignment is possible so long as you manage the plans variables.

©2012 Endo Pharmaceuticals Inc. All rights reserved.

9
Oh boy … the plans! I didn’t want to read any of them
– Loads of variables
– $75,000* total cost for one
– Had to tease out
–
–
–
–

the redundant
the confounding
the conflicting
the work-inducing

– 90%** is NOT REGULATED
*I did not make this up
**I made this up

We needed a timeout!

©2012 Endo Pharmaceuticals Inc. All rights reserved.

10
forcing a slowdown at startup

©2012 Endo Pharmaceuticals, Inc. All rights reserved.

11
©2012 Endo Pharmaceuticals Inc. All rights reserved.

12
Kick off meeting Study team preparation

©2012 Endo Pharmaceuticals Inc. All rights reserved.

13
Attention here please

©2012 Endo Pharmaceuticals Inc. All rights reserved.

14
pre-prep preparation… JDI

© 2012 Endo Pharmaceuticals Inc. All rights reserved.

15
The CI is not the only one waiting for a final protocol

Sometimes it is a game to see who can hold out the longest.

©2012 Endo Pharmaceuticals Inc. All rights reserved.

16
And They’re Off!

Final protocol to FPI: 12 weeks
ICF
CRF
DMP
DRP
SAP
Safety Plan
IDMC Charter
Monitoring Plan
Escalation Plan
Communication Plan
Clinical Supplies Plan
File Management Plan
Medical Monitoring Plan
Sponsor Oversight Plan
Project Management Plan

©2012 Endo Pharmaceuticals Inc. All rights reserved.

17
©2012 Endo Pharmaceuticals Inc. All rights reserved.

18
Hold up – deconstruct the protocol before inking any plans
–
–
–
–
–
–
–
–

Dissect for data
Make an inventory
Tie-back to protocol objectives
Take out the WANTs, leave the NEEDs
Dispense with the notion of a CRF page
Identify a single point of origin for every item
Draw a map to illustrate how it flows end to end
Know how and where it will be presented in the study report

– Accept this is an iterative process and it will be revisited. This is okay.

Ask the questions no one else wants to, confront the risks early and often.

©2012 Endo Pharmaceuticals Inc. All rights reserved.

19
Plans we find useful in a global, multi-regional study

protocol

–

the

–

a 2-page
tells us at a glance where we have transferred
obligations, the names of the people working our study and which organization’s SOPs are being followed

–

a PPT document with lots of white space called the
completed by our service partners

–

the
tasks based on study risk analyses

–

an
what, when, how and who without replication of content that should be sourced elsewhere

Sponsor Oversight Plan

playbook that documents the plays for the tasks

global monitoring plan that describes expectations for on-site and centralized monitoring

integrated data management & review plan that describes the

+ The most overlooked: the plan to share it all with our sites.

©2012 Endo Pharmaceuticals Inc. All rights reserved.

20
site & study initiation

©2012 Endo Pharmaceuticals Inc. All rights reserved.

21
New (?) approach to training
– Study Initiation Meeting
– No longer PI centric, no silo presentations
– Advance enlistment of trusted sites
– tell them they are coming along the way
– start them up early & invest too much time
– engage them in planning

– Integrated delivery of study information
– simulate screening a subject & processing through study

– Service & technology providers are team members
– Study team intends to learn as much as they teach

First be armed with real-world qualitative experience, then go large.

©2012 Endo Pharmaceuticals Inc. All rights reserved.

22
Build a sense of community & keep it online

©2012 Endo Pharmaceuticals Inc. All rights reserved.

23
final thought
Do More, Plan Less: Data Quality Deconstructed at Global Clinical Trials

Más contenido relacionado

Similar a Do More, Plan Less: Data Quality Deconstructed at Global Clinical Trials

Regulatory Challenges In Executing Clinical Trials Globally
Regulatory Challenges In Executing Clinical Trials GloballyRegulatory Challenges In Executing Clinical Trials Globally
Regulatory Challenges In Executing Clinical Trials GloballyMichael Swit
 
RiskAssessmentCBIFalcon25June2012
RiskAssessmentCBIFalcon25June2012RiskAssessmentCBIFalcon25June2012
RiskAssessmentCBIFalcon25June2012Robert Falcon
 
Sanofi mongodb-world-20140625-final
Sanofi mongodb-world-20140625-finalSanofi mongodb-world-20140625-final
Sanofi mongodb-world-20140625-finalMongoDB
 
Back in Business: Information Every Idaho Employer Should Know
Back in Business: Information Every Idaho Employer Should KnowBack in Business: Information Every Idaho Employer Should Know
Back in Business: Information Every Idaho Employer Should KnowParsons Behle & Latimer
 
The Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis Liability
The Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis LiabilityThe Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis Liability
The Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis LiabilityMichael Swit
 
Presentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-Founder
Presentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-FounderPresentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-Founder
Presentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-FounderHealth IT Conference – iHT2
 
Icd 10 and icd10 medical policy health plan under hipaa
Icd 10 and icd10 medical policy health plan under hipaaIcd 10 and icd10 medical policy health plan under hipaa
Icd 10 and icd10 medical policy health plan under hipaaMichael Arrigo
 
Drug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory EnvironmentDrug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory EnvironmentMichael Swit
 
Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14DupontInv
 
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTMichael Swit
 
ePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrime
ePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrimeePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrime
ePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrimeCindy Howry, MS
 
FDA Regulation of Promotion & Advertising -- Part 8: Handling Promotional Co...
FDA Regulation of Promotion & Advertising -- Part 8:  Handling Promotional Co...FDA Regulation of Promotion & Advertising -- Part 8:  Handling Promotional Co...
FDA Regulation of Promotion & Advertising -- Part 8: Handling Promotional Co...Michael Swit
 
ePRO_Presentation_BYOD Webinar_10Mar2016_FINAL
ePRO_Presentation_BYOD Webinar_10Mar2016_FINALePRO_Presentation_BYOD Webinar_10Mar2016_FINAL
ePRO_Presentation_BYOD Webinar_10Mar2016_FINALjencrager
 
The Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James CrawfordThe Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James CrawfordKnome_Inc
 
Regulatory Challenges to Successful Global Clinical Studies
Regulatory Challenges to Successful Global Clinical StudiesRegulatory Challenges to Successful Global Clinical Studies
Regulatory Challenges to Successful Global Clinical StudiesMichael Swit
 
Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...
Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...
Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...www.datatrak.com
 
Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...
Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...
Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...RikuE
 

Similar a Do More, Plan Less: Data Quality Deconstructed at Global Clinical Trials (20)

Regulatory Challenges In Executing Clinical Trials Globally
Regulatory Challenges In Executing Clinical Trials GloballyRegulatory Challenges In Executing Clinical Trials Globally
Regulatory Challenges In Executing Clinical Trials Globally
 
RiskAssessmentCBIFalcon25June2012
RiskAssessmentCBIFalcon25June2012RiskAssessmentCBIFalcon25June2012
RiskAssessmentCBIFalcon25June2012
 
Sanofi mongodb-world-20140625-final
Sanofi mongodb-world-20140625-finalSanofi mongodb-world-20140625-final
Sanofi mongodb-world-20140625-final
 
MINDS-ON | Impact COVID19 on Clinical Trials
MINDS-ON | Impact COVID19 on Clinical TrialsMINDS-ON | Impact COVID19 on Clinical Trials
MINDS-ON | Impact COVID19 on Clinical Trials
 
Back in Business: Information Every Idaho Employer Should Know
Back in Business: Information Every Idaho Employer Should KnowBack in Business: Information Every Idaho Employer Should Know
Back in Business: Information Every Idaho Employer Should Know
 
The Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis Liability
The Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis LiabilityThe Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis Liability
The Small Company Clinical Study Sponsor -- Roles & Duties Vis-à-vis Liability
 
Presentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-Founder
Presentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-FounderPresentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-Founder
Presentation "7 Ideas in 7 Minutes" with Jason Bhan, MD, EVP, CMO, Co-Founder
 
NUS PRIME (Zubin)
NUS PRIME (Zubin)NUS PRIME (Zubin)
NUS PRIME (Zubin)
 
Icd 10 and icd10 medical policy health plan under hipaa
Icd 10 and icd10 medical policy health plan under hipaaIcd 10 and icd10 medical policy health plan under hipaa
Icd 10 and icd10 medical policy health plan under hipaa
 
Drug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory EnvironmentDrug Development in Today's Regulatory Environment
Drug Development in Today's Regulatory Environment
 
Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14
 
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENTREGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
REGULATORY AND OTHER PITFALLS IN DRUG DEVELOPMENT
 
ePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrime
ePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrimeePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrime
ePRO_Presentation_BYOD Webinar_5 Final 9 March 2016 YPrime
 
FDA Regulation of Promotion & Advertising -- Part 8: Handling Promotional Co...
FDA Regulation of Promotion & Advertising -- Part 8:  Handling Promotional Co...FDA Regulation of Promotion & Advertising -- Part 8:  Handling Promotional Co...
FDA Regulation of Promotion & Advertising -- Part 8: Handling Promotional Co...
 
ePRO_Presentation_BYOD Webinar_10Mar2016_FINAL
ePRO_Presentation_BYOD Webinar_10Mar2016_FINALePRO_Presentation_BYOD Webinar_10Mar2016_FINAL
ePRO_Presentation_BYOD Webinar_10Mar2016_FINAL
 
The Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James CrawfordThe Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James Crawford
 
Running Head CIGO .docx
Running Head CIGO                                                .docxRunning Head CIGO                                                .docx
Running Head CIGO .docx
 
Regulatory Challenges to Successful Global Clinical Studies
Regulatory Challenges to Successful Global Clinical StudiesRegulatory Challenges to Successful Global Clinical Studies
Regulatory Challenges to Successful Global Clinical Studies
 
Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...
Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...
Utilizing a Unified Platform to Bridge Geographical and Departmental Gaps Whi...
 
Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...
Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...
Rena Eichler - Those Devilish Details:P4P Design and Implementation Considera...
 

Más de ConferenceForum

Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...ConferenceForum
 
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsStrategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsConferenceForum
 
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkThomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkConferenceForum
 
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsGCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsConferenceForum
 
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...ConferenceForum
 
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerChanging Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerConferenceForum
 
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012ConferenceForum
 
Podd slide deck mark kontny
Podd slide deck   mark kontnyPodd slide deck   mark kontny
Podd slide deck mark kontnyConferenceForum
 
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1ConferenceForum
 
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012ConferenceForum
 

Más de ConferenceForum (20)

Steve Hoffmann
Steve HoffmannSteve Hoffmann
Steve Hoffmann
 
A Peek at Dpharm 2012
A Peek at Dpharm 2012A Peek at Dpharm 2012
A Peek at Dpharm 2012
 
A Peek at CMO East 2013
A Peek at CMO East 2013A Peek at CMO East 2013
A Peek at CMO East 2013
 
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
 
A Peek at GCT 2012
A Peek at GCT 2012A Peek at GCT 2012
A Peek at GCT 2012
 
A Peek at Dpharm 2012
A Peek at Dpharm 2012A Peek at Dpharm 2012
A Peek at Dpharm 2012
 
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsStrategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
 
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkThomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
 
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsGCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging Markets
 
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
 
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerChanging Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz Stoner
 
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Podd slides 1
Podd slides 1Podd slides 1
Podd slides 1
 
Podd slides
Podd slidesPodd slides
Podd slides
 
Podd slide deck mark kontny
Podd slide deck   mark kontnyPodd slide deck   mark kontny
Podd slide deck mark kontny
 
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1
 
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012
 

Último

MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?Olivia Kresic
 
Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03DallasHaselhorst
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyotictsugar
 
Intro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdfIntro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdfpollardmorgan
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfJos Voskuil
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckHajeJanKamps
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxMarkAnthonyAurellano
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCRashishs7044
 
Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionMintel Group
 
8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCR8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCRashishs7044
 
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / NcrCall Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncrdollysharma2066
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCRashishs7044
 
FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607dollysharma2066
 
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...ShrutiBose4
 
Buy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy Verified Accounts
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...ictsugar
 
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCRashishs7044
 

Último (20)

MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?
 
Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03Cybersecurity Awareness Training Presentation v2024.03
Cybersecurity Awareness Training Presentation v2024.03
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyot
 
Intro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdfIntro to BCG's Carbon Emissions Benchmark_vF.pdf
Intro to BCG's Carbon Emissions Benchmark_vF.pdf
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdf
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
 
Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted Version
 
8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCR8447779800, Low rate Call girls in Saket Delhi NCR
8447779800, Low rate Call girls in Saket Delhi NCR
 
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / NcrCall Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
Call Girls in DELHI Cantt, ( Call Me )-8377877756-Female Escort- In Delhi / Ncr
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR
 
FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607FULL ENJOY Call girls in Paharganj Delhi | 8377087607
FULL ENJOY Call girls in Paharganj Delhi | 8377087607
 
Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)
 
Enjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCR
Enjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCREnjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCR
Enjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCR
 
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
Ms Motilal Padampat Sugar Mills vs. State of Uttar Pradesh & Ors. - A Milesto...
 
Buy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail AccountsBuy gmail accounts.pdf Buy Old Gmail Accounts
Buy gmail accounts.pdf Buy Old Gmail Accounts
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
 
Corporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information TechnologyCorporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information Technology
 
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
 

Do More, Plan Less: Data Quality Deconstructed at Global Clinical Trials

  • 1. Data Quality Deconstructed: Do more, plan less Global Clinical Trials 14-Sep-2012 Boston Eileen M. Daniel Director, Clinical & Data Operations ©2012 Endo Pharmaceuticals, Inc. All rights reserved. 1
  • 2. 15+ years ago New York City Spring 1997 ©2012 Endo Pharmaceuticals Inc. All rights reserved. 2
  • 3. Today there is nothing new under the sun … except maybe some clouds ©2012 Endo Pharmaceuticals Inc. All rights reserved. 3
  • 4. During this talk, I will – – – – – remind us of fundamentals provide facts about a global study tell you where & why we liberally apply brakes flashback to a deconstruction methodology close with thoughts on site and study initiation ©2012 Endo Pharmaceuticals Inc. All rights reserved. 4
  • 5. stating the obvious ©2012 Endo Pharmaceuticals, Inc. All rights reserved. 5
  • 6. We all know this The clinical trials we sponsor are research studies. – A study is conducted according to a well-defined study plan – That well-defined study plan is the protocol Clinical investigators are responsible for conducting studies in accordance with the protocol. We are obliged to oversee and keep sharp focus on: – Protection of human subjects – Integrity of study data – Compliance with applicable regulations To meet our oversight obligations we conspire to plan. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 6
  • 7. the plans (sigh) © 2012 Endo Pharmaceuticals Inc. All rights reserved. 7
  • 8. The plans for a global phase 3 study – 3.5 FTEs with global responsibility study leader | data manager | study specialist | clinical information mgr – 450 subjects recruited from 120 sites North America, Europe, India – 10 service partners including 4 CROs – All study data flows in electronically from three sources eCRF, central laboratory, IVRS – 1 protocol, 1 playbook and 7 global plans Bladder cancer is challenging enough. Starting up was hard to do. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 8
  • 9. Starting up – forming our global study community study community study community >600 +clinical investigators & team study team >30 study team clinical sub team clinical trial manager +partner project managers clinical sub-team >10 trial manager research scientist statistician data manager project management regulatory affairs health economics pharmacovigilance … Alignment is possible so long as you manage the plans variables. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 9
  • 10. Oh boy … the plans! I didn’t want to read any of them – Loads of variables – $75,000* total cost for one – Had to tease out – – – – the redundant the confounding the conflicting the work-inducing – 90%** is NOT REGULATED *I did not make this up **I made this up We needed a timeout! ©2012 Endo Pharmaceuticals Inc. All rights reserved. 10
  • 11. forcing a slowdown at startup ©2012 Endo Pharmaceuticals, Inc. All rights reserved. 11
  • 12. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 12
  • 13. Kick off meeting Study team preparation ©2012 Endo Pharmaceuticals Inc. All rights reserved. 13
  • 14. Attention here please ©2012 Endo Pharmaceuticals Inc. All rights reserved. 14
  • 15. pre-prep preparation… JDI © 2012 Endo Pharmaceuticals Inc. All rights reserved. 15
  • 16. The CI is not the only one waiting for a final protocol Sometimes it is a game to see who can hold out the longest. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 16
  • 17. And They’re Off! Final protocol to FPI: 12 weeks ICF CRF DMP DRP SAP Safety Plan IDMC Charter Monitoring Plan Escalation Plan Communication Plan Clinical Supplies Plan File Management Plan Medical Monitoring Plan Sponsor Oversight Plan Project Management Plan ©2012 Endo Pharmaceuticals Inc. All rights reserved. 17
  • 18. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 18
  • 19. Hold up – deconstruct the protocol before inking any plans – – – – – – – – Dissect for data Make an inventory Tie-back to protocol objectives Take out the WANTs, leave the NEEDs Dispense with the notion of a CRF page Identify a single point of origin for every item Draw a map to illustrate how it flows end to end Know how and where it will be presented in the study report – Accept this is an iterative process and it will be revisited. This is okay. Ask the questions no one else wants to, confront the risks early and often. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 19
  • 20. Plans we find useful in a global, multi-regional study protocol – the – a 2-page tells us at a glance where we have transferred obligations, the names of the people working our study and which organization’s SOPs are being followed – a PPT document with lots of white space called the completed by our service partners – the tasks based on study risk analyses – an what, when, how and who without replication of content that should be sourced elsewhere Sponsor Oversight Plan playbook that documents the plays for the tasks global monitoring plan that describes expectations for on-site and centralized monitoring integrated data management & review plan that describes the + The most overlooked: the plan to share it all with our sites. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 20
  • 21. site & study initiation ©2012 Endo Pharmaceuticals Inc. All rights reserved. 21
  • 22. New (?) approach to training – Study Initiation Meeting – No longer PI centric, no silo presentations – Advance enlistment of trusted sites – tell them they are coming along the way – start them up early & invest too much time – engage them in planning – Integrated delivery of study information – simulate screening a subject & processing through study – Service & technology providers are team members – Study team intends to learn as much as they teach First be armed with real-world qualitative experience, then go large. ©2012 Endo Pharmaceuticals Inc. All rights reserved. 22
  • 23. Build a sense of community & keep it online ©2012 Endo Pharmaceuticals Inc. All rights reserved. 23